Literature DB >> 9192789

Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.

M O Arcasoy1, B A Degar, K W Harris, B G Forget.   

Abstract

Familial erythrocytosis (familial polycythemia) inherited as an autosomal dominant trait has recently been reported to be associated with mutations in the gene encoding the erythropoietin receptor (EpoR) in a small number of families. We studied a new kindred with dominantly inherited familial erythrocytosis associated with heterozygosity for a deletion of seven nucleotides between positions 5985 and 5991 in exon 8 of the EpoR gene, resulting in an EpoR peptide that is truncated by 59 amino acids at its C-terminus. A 7-bp direct repeat is present in the normal EpoR gene at the site of this mutation, consistent with the slipped mispairing model for the generation of short deletions during DNA replication. Hypersensitivity to Epo of erythroid progenitors from an affected individual was observed in in vitro methylcellulose cultures, as indicated by more numerous and larger colonies compared with those of a control subject. To study mutant EpoR function, the cDNA encoding the mutant EpoR was synthesized by reverse transcription-polymerase chain reaction of peripheral blood RNA from the proband and stably tranfected into murine interleukin-3-dependent 32D cells. Epo dose-response assays showed that cells expressing the mutant EpoR displayed fivefold to 10-fold increased sensitivity to Epo compared with cells expressing similar numbers of the wild-type EpoR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192789

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Authors:  Que T Lambert; Anuradha Pradhan; J Devon Roll; Gary W Reuther
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

Review 2.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

3.  The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis.

Authors:  H Zang; K Sato; H Nakajima; C McKay; P A Ney; J N Ihle
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

4.  Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells.

Authors:  Lei Wang; Murat O Arcasoy; Stephanie S Watowich; Bernard G Forget
Journal:  Exp Hematol       Date:  2005-03       Impact factor: 3.084

5.  Familial polycythemia due to truncations of the erythropoietin receptor.

Authors:  B G Forget; B A Degan; M O Arcasoy
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

6.  A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia.

Authors:  Kacey O'Rourke; David J Fairbairn; Kathryn A Jackson; Kirk L Morris; Siok-Keen Tey; Glen A Kennedy
Journal:  Int J Hematol       Date:  2011-03-25       Impact factor: 2.490

Review 7.  The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.

Authors:  Stephanie S Watowich
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

Review 8.  Advances in understanding the pathogenesis of primary familial and congenital polycythaemia.

Authors:  Lily J Huang; Yu-Min Shen; Gamze B Bulut
Journal:  Br J Haematol       Date:  2010-01-20       Impact factor: 6.998

9.  Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia.

Authors:  R Kralovics; L Sokol; J T Prchal
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 10.  Erythrocytosis: genes and pathways involved in disease development.

Authors:  Jernej Gašperšič; Aleša Kristan; Tanja Kunej; Irena Preložnik Zupan; Nataša Debeljak
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.